45 results about "Free cholesterol" patented technology

The present invention relates to free cholesterol analogs bearing a boron dipyrromethene difluoro (BODIPY) fluorophore in the side chain and methods of preparation. The compounds of the present invention can be used in fluorescence spectroscopy and fluorescence microscopy to visualize the exchange, distribution, and trafficking of free cholesterol between living cells and to monitor the movement of free cholesterol between ordered and disordered lipid domains in membranes.

This invention discloses an associating determination and reagent about high and low-density lipoprotein cholesterol. It utilizes affinity difference between lipoprotein and surface activator, adds agent one and agent two, and with the action of the assembling ionic surface activator, the CM, VLDL and LDL-C or HDL-C in the serum form the soluble complex, the extricate cholesterol generates H#-[2]O#-[2] with the catalytic reaction of cholesterol esterase (CHER) and cholesterol oxidase (CHO), and with the action of peroxydase (POD), the H#-[2]O#-[2] is cleared, and adds agent three, as with the action of a specific selective surface activator, only HDL-C or LDL-C granule is soluble, so with action of Trinder one can determine the content of HDL-C and LDL-C.

The invention discloses a method for determining cholesterol by using flow injection chemiluminescence with nano-copper oxide as a catalyst. The method comprises the following steps: mixing cholesterol, cholesterol oxidase and phosphatic buffer solution; warm bathing the mixture solution to obtain a reaction solution; after diluting the reaction solution, inputting the diluted reaction solution into a mixer through a peristaltic pump to mix with a nano-copper oxide colloidal solution; then mixing with a luminol solution; entering into a flow cell for reaction; and detecting the generated chemiluminescence intensity by a photomultiplier to determine the cholesterol. By using cholesterol oxidase for catalyzing the oxidation of cholesterol to generate hydrogen peroxide, combining the flow injection technique, the chemiluminescence signal in the determination of cholesterol is enhanced about 600 times. By using cholesterol-cholesterol oxidase-luminol-nano-copper oxide flow injection chemiluminescence to determine the cholesterol content, the linear range is 0.625-12.5 [mu]mol / L. the method can be used for determination of food cholesterol content and determination of the free cholesterol and total cholesterol in serum.

A method for treating an immune-related disorder in a patient comprising administering an agent to the patient for altering the patient's plasma concentration of free cholesterol, wherein said agent is a non-statin agent and is administered in an amount sufficient to modulate the immune-related disorder.

Ester-form and free-form cholesterols contained in a very-low-density lipoprotein remnant (hereinafter, inclusively referred to as very-low-density lipoprotein remnant cholesterols) are determined. In an aqueous medium containing a sample, a cholesterol ester hydrolase and a cholesterol oxidase or cholesterol dehydrogenase are caused to act specifically on the very-low-density lipoprotein remnant cholesterols in the sample in the presence of a combination of (a) a polyoxyethylene-polyoxyalkylene alkylaryl ether and (b) at least one surfactant selected from the group consisting of a polyoxyethylene / polyoxybutylene condensate, a polyoxyethylene styrenated phenyl ether, and a polyoxyalkylene long-chain alkyl ether.

This application discloses methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and / or phospholipid content in the lipoprotein particles. Methods of treating a subject at increased risk for cardiovascular disease and / or cardiodiabetes are also disclosed.

The invention provides a method for removing total cholesterol in animal fat. The method comprises the following steps: first, esterification is performed, animal fat is subjected to an esterification reaction under action of catalysts; second, adsorption is performed, the products after esterification reaction are contacted with adsorbents; third, the products after adsorption reaction is subjected to solid-liquid separation. In the method, no extra reaction substrates need to be added, no superfluous reactants need to be removed in the subsequent separating and processing steps, and the operation is simple. The polarity of the products after esterification weakens, and the products are easy to be absorbed by the adsorbents. The removing rates of free cholesterol and total cholesterol through the esterification and adsorption two-step method are both higher than that only through an adsorption method.

The invention relates to a non-invasive skin free-cholesterol detection device for evaluating the atherosclerosis risk. A palm part of a tester is coated with a specific reagent, the relative content of free cholesterol on the skin of the tester can be acquired by measuring the variation situation of a reaction reagent reflection spectrum by utilizing an optical method, and then the risk for a subject suffering the atherosclerosis disease can be further evaluated.

The invention discloses a two-step enzymatic determination method for cholesterol ester in serum, which belongs to the field of methods for testing materials through color change of test reaction results by utilizing visible light. The technical scheme of the invention is as follows: a reagent II only contains effective components of hydrolase of the cholesterol ester, and bi-color original substances and other effective components are contained in a reagent I; and the determination method is as follows: firstly carrying out warm bath on the serum and the reagent I for 3-5min at 37 DEG C, leading free cholesterol in the serum to be reacted with the reagent I to generate quinonimine, adding the reagent II, then carrying out the warm bath for 4-7min at 37 DEG C, generating the cholesterol after hydrolysis of the cholesterol ester, and carrying out reaction for generating the red quinonimine. An instrument is used for detecting at the wavelength of 500nm-520nm, the quinonimine generated by the reaction of the reagent I is taken as blank, and the quinonimine generated by the reaction of the reagent II can be used for determining the content of the cholesterol ester. The method can not be affected by the endogenous free cholesterol during the detection, and the using method and the range are the same with the original two-step enzymatic method, thereby being the cholesterol ester detection method with quickness and higher accuracy.

A method of a pretreatment of a sample for quantitating cholesterol characterized by, before measuring cholesterol contained in specific lipoproteins, treating the sample containing lipoproteins with an enzyme, the substrate of which is free cholesterol, optionally together with a reaction accelerator; a method for quantitating cholesterol in specific lipoproteins by using the above method; and a kit for quantitating cholesterol in specific lipoproteins to be used in the above quantification method. By using this quantification method, cholesterol in a specific fraction can be conveniently, accurately and efficiently quantitated fundamentally without resort to polyanion, etc. Thus, this method is appropriately usable in various automatic analyzers.

The invention discloses artificial bezoar and a preparation method thereof, and relates to the technical field of production formula and technology of medicine. Sodium bilirubinate, calcium bilirubinate, cholic acid, taurodeoxycholic acid or hyodesoxycholic acid, combined cholesterol or free cholesterol, combined taurine or free taurine or mixture of the combined taurine and the free taurine, ox-bile powder or porcine-bile powder are mixed and grinded into powder. The artificial bezoar contains the sodium bilirubinate, the calcium bilirubinate and other components same as natural bezoar, but does not contain free bilirubin; and the total bilirubin has a constant content of more than 0.1 to 35 percent. The components of each batch of the artificial bezoar are consistent. The artificial bezoar contains no harmful bacteria, virus or ascaris eggs; and the efficacy is higher than the prior artificial bezoar but is equal to the natural bezoar.

The invention discloses a novel method for preparing calculus bovis factitius and raw materials thereof. The method comprises the following steps: weighing the following components in percentage by weight: 20-30 percent of calcium bilirubinate, 10-20 percent of sodium bilirubinate, 3-8 percent of taurine, 20-30 percent of deoxycholic acid, 2-5 percent of cholic acid or hyocholic acid, 2-5 percent of binding cholesterol or free cholesterol, 2-5 percent of zinc sulfate and 2-5 percent of magnesium sulfate; stirring for 20-60 minutes, adding the balance of ox gallbladder powder, and keeping on stirring for 20-60 minutes to obtain the calculus bovis factitius. According to the method for preparing calcium bilirubinate and sodium bilirubinate serving as effective components in the calculus bovis factitius, high-quality calculus bovis factitius is prepared according to a specific proportion, and the requirement of market for performance of calculus bovis factitius can be met.

The invention relates to compositions, medicaments, methods for treating individuals with high plasma lipid levels, and methods for screening drug candidates useful in, for example, the treatment of hypercholesterolemia. Specifically, the invention relates to the discovery that MTP inhibition leads to increased accumulation in cellular free-cholesterol and is useful in the development of compositions, medicaments, methods of treatment and drug screening methods to treat high plasma lipid levels.

The invention relates to a folic acid modified norcantharidin stealth niosome and a preparation method thereof. The niosome is a surface hydrophilic and folic acid modified stealth niosome which is formed by entrapping norcantharidin with a poloxamer 407-cholesterol compound and a folic acid-polymer as major carrier materials; and the stealth niosome contains no free cholesterol. The entrapment rate of the niosome is (52.30+ / -2.16)%, the mean grain size of the niosome is (100.87+ / -0.23)nm and the zeta potential of the niosome is -25.96 mV; the drug release rate in vitro of the niosome is obviously lower than that of a crude drug; t1 / 2 released by the niosome in an environment in which the pH of 7.4 of the normal tissue is simulated is 1.98 times of that released by the niosome in an environment in which the pH of 5.0 of the normal tissue is simulated; and the folic acid modified norcantharidin stealth niosome is obvious in slow release effect and advantageous for releasing in target cells. Besides, the niosome is capable of obviously increasing the growth inhibition ratio and drug taking quantity of tumor cells, and generating active targeting effect at molecular level, and therefore, the efficacy of the drug is improved, treatment of cancer at high efficiency and low toxicity is facilitated.

A pharmacologically acceptable emulsion of biocompatible solvent microdroplets is provided for treating atherosclerosis, heart disease and stroke. Intravenous administration of the biocompatible solvent microdroplets enables the microdroplets to bind and dissolve free cholesterol, cholesterol esters or other fatty compounds within the plaque. A high level of selectivity is ensured from energy principals, by designing the microdroplets to have a low interfacial surface energy when binding to free cholesterol or cholesterol esters in arterial plaque and a high interfacial surface energy when coming into contact with blood cells or endothelial cells along the walls of blood vessels. A review of many compounds which may form the basis of the biocompatible solvent from which the microdroplets are fabricated, as well as their solubility parameters are provided. Furthermore, a specially designed catheter with a micromachined tip is also provided to allow the microdroplets to be generated directly within a blood vessel, as an alternative to emulsification.

A concentration of cholesterol ester or free cholesterol can be calculated using the concentrations of total cholesterol and triglyceride in lipoproteins contained in a sample. Further, a concentration of lipoprotein particles in a fraction can be calculated using the lipoprotein particle size in the fraction. The concentrations of total cholesterol and triglyceride contained in a subject sample are detected. Using the concentrations of total cholesterol and triglyceride thus detected, the concentration of cholesterol ester or free cholesterol is calculated. Further, using the concentration of cholesterol ester or free cholesterol thus calculated, the concentration of lipoprotein particles in a fraction can be calculated.

A compound for use as a medicament for the modulation of angiogenesis through the tackling of the intracellular free cholesterol-caveolin1-eNOS-NO pathway.

The invention belongs to the technical field of application of edible fat, and particularly discloses a preparation method of transesterification butterfat. The preparation method comprises the following steps of step (1), heating 3 tons of natural anhydrous butter to 33-37 DEG C, and performing stirring to enable the natural anhydrous butter to melt; step (2) maintaining the temperature stable, adding lipases of certain concentration as a catalyst, and performing a reaction for 18-24 hours; and step (3), after the reaction is completed, performing heating to 85 DEG C for inactivating enzymes.The preparation method and application of the transesterification butterfat have the beneficial effects that the lipases is used for transesterification, so that free cholesterol contained in the butterfat can react to obtain esterified cholesterol, the absorption rate is reduced, and the obesity risk can be reduced. In the process, the content of myristic acid is also reduced (detection proves that C14:0 is reduced to about 2% from 10%), the content of stearic acid is increased (detection proves that C18:0 is increased to about 14% from 12%, C18:1 is increased to about 40% from 26%, and C18:2 is increased to about 14% from 3%).

It is intended to find an efficient method of searching for drugs affecting the cholesteryl ester cycle and establish a system of efficiently searching for defoaming agents or regression agents artherosclerotic lesion and a system of searching for therapeutic agents remedies for atherosclerosis with a mechanism different from publicly known ones. A method of evaluating effects of a test substance on intracellular cholesteryl ester metabolic regulation which comprises selectively extracting free cholesterol with an aqueous alcohol from cells having been incubated in the presence of the test substance and cells having been incubated in the absence of the test substance, and then comparing the cholesteryl ester content in the cells having been incubated in the presence of the test substance with the cholesteryl ester content in the cells having been incubated in the absence of the test substance; in particular, a method of screening a compound having an activity of regulating the intracellular cholesteryl ester metabolism; and defoaming promoters, antiatherogenic agents or agents for regression of atherosclerotic lesion containing as the active ingredient compounds screened by the above method.

The invention discloses a free cholesterol assay kit and a use method thereof. The free cholesterol assay kit comprises a first detection liquid and a second detection liquid, wherein the first detection liquid comprises polyethylene glycol, ascorbic acid oxidase and peroxidase according to the concentration ratio being (1 to 3):(4 to 6):(9 to 11); the second detection liquid comprises 4- aminoantipyrine, peroxidase and cholesterol oxidase according to the concentration ratio being (1 to 3):(9 to 11):(4 to 6). By adopting an enzymic colorimetric method, the free cholesterol assay kit and the use method thereof disclosed by the invention have the advantages of simplicity in operation, high accuracy and convenience in popularization.

Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.

This invention relates to methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and / or phospholipid content in the lipoprotein particles. The invention also relates to the use of the assessed quantities of the lipoprotein particles or portions thereof to determine whether a subject is at increased risk for cardiovascular diseases and cardiodiabetes.

A concentration of cholesterol ester or free cholesterol can be calculated using the concentrations of total cholesterol and triglyceride in lipoproteins contained in a sample. Further, a concentration of lipoprotein particles in a fraction can be calculated using the lipoprotein particle size in the fraction. The concentrations of total cholesterol and triglyceride contained in a subject sample are detected. Using the concentrations of total cholesterol and triglyceride thus detected, the concentration of cholesterol ester or free cholesterol is calculated. Further, using the concentration of cholesterol ester or free cholesterol thus calculated, the concentration of lipoprotein particles in a fraction can be calculated.

The invention discloses a method for determining very low density lipoprotein (VLDL) subcomponents and component distribution thereof. The method comprises the following steps of (1) according to density of VLDL, dividing the total VLDL into 2-5 subcomponents, and determining contents of triglyceride, cholesterol, free cholesterol and phospholipid in each subcomponent; (2) calculating the ratio of triglyceride in each sub-component to total triglyceride in each sub-component, and calculating the ratio of cholesterol, free cholesterol and phospholipid according to the same method to obtain the distribution condition of the VLDL component in each sub-component; and (3) according to the individual time / intervention process, carrying out multiple times of measurement, and comparing the change condition of the distribution of each component. When individual diseases or abnormal lipid metabolism occur and the detection result of the total very low density lipoprotein is stable, the method can reflect the change state of the individual lipid metabolism according to the distribution change rule of the triglyceride, the cholesterol, the free cholesterol and the phospholipid in the subfractions.

The invention relates to the technical field of total cholesterol detection, in particular to a total cholesterol detection reagent and a detection chip. According to the total cholesterol detection reagent and the detection chip provided by the embodiment of the invention, cholesterol ester in a detection sample can be hydrolyzed into free cholesterol under the action of cholesterol esterase, the free cholesterol is reduced into cholane-4-ene-3-ketone by cholesterol dehydrogenase, and meanwhile, oxidized coenzyme I is reduced into reduced coenzyme I. The content of total cholesterol in a detection sample can be determined by detecting the absorbance of the reduced coenzyme I, the operation is simple, and the reaction process is not easily interfered by other substances (such as ascorbic acid, bilirubin, hemoglobin, triglyceride and lactic dehydrogenase). Therefore, the detection result is more accurate.

A pharmacologically acceptable emulsion of biocompatible solvent microdroplets is provided for treating atherosclerosis, heart disease and stroke. Intravenous administration of the biocompatible solvent microdroplets enables the microdroplets to bind and dissolve free cholesterol, cholesterol esters or other fatty compounds within the plaque. A high level of selectivity is ensured from energy principals, by designing the microdroplets to have a low interfacial surface energy when binding to free cholesterol or cholesterol esters in arterial plaque and a high interfacial surface energy when coming into contact with blood cells or endothelial cells along the walls of blood vessels. A review of many compounds which may form the basis of the biocompatible solvent from which the microdroplets are fabricated, as well as their solubility parameters are provided. Furthermore, a specially designed catheter with a micromachined tip is also provided to allow the microdroplets to be generated directly within a blood vessel, as an alternative to emulsification.

The invention discloses a preparation method of a fat-free cholesterol-free lactic acid bacteria beverage fermented with egg white. The method comprises the following steps of separating yolk from eggwhite; mixing the egg white with water, carbohydrate substances, sodium acetate, citric acid triamine and inorganic salts in proportion, performing uniform stirring, and performing heating to 70-90 DEG C so as to obtain liquid to be fermented; after heating is completed, cooling the liquid to be fermented, then adding a fermenting agent, performing uniform mixing, and performing constant-temperature fermentation; and sequentially performing dispersing, homogenizing, cold storage and after-ripening on fermentation products so as to obtain the fat-free cholesterol-free lactic acid bacteria beverage. According to the preparation method disclosed by the invention, the market blank of high-protein beverages is filled, and the fermentation of the lactic acid bacteria beverage is performed withthe egg white; besides, through heating, antifungal protein is denatured, the antibacterial activity is restrained, and growth of lactic acid bacteria is promoted; and besides, through adding the carbohydrate substances, the inorganic salts and the growth factors, favorable conditions are provided for the growth of the lactic acid bacteria, so that the fat-free cholesterol-free lactic acid bacteria beverage which is large in the number of the lactic acid bacteria and rich in protein content is obtained.

The invention discloses a measuring method of high density lipoprotein cholesterol fraction esterification velocity, which comprises: a) adding a lecithin cholesterol acyltransferase activity inhibitor in a fresh whole blood sample; b) adding a precipitator to obtain a sample only containing high density lipoprotein; c) dividing the sample into two parts with one part added with a lecithin cholesterol acyltransferase activity restorer and the other part added with nothing, and the two parts are cultivated at a temperature of 37 DEG C for one hour; and d) utilizing the high efficiency liquid phase chromatography to respectively measure high density lipoprotein free cholesterol of the two samples and calculating the difference between the two parts, and obtaining the high density lipoprotein cholesterol fraction esterification velocity by dividing the difference value by the detected percentage of high density lipoprotein free cholesterol of the sample without adding lecithin cholesterol acyltransferase activity restorer. The method of the invention has advantages of simplicity, safety, low cost and storability of samples.